PTPRC and neoplasm: Immunohistochemistry analysis of mouse and human CRC tumour tissues validated the findings described in the subcutaneous xenograft and genetic tumour models, including alleviation of tumour hypoxia, reduction of CD31+ microvessels, reduced tumour cell proliferation and decreased CD45+ populations (Extended Data Fig. 3c–f).